Abstract： The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)vaccine is one of the most effective weapons to fight the coronavirus disease 2019(COVID-19)pandemic(Lazarus et al.,2022).Among all SARS-CoV-2 vaccines generated on different platforms,those consisting of the inactivated virus,such as BBIBP-CorV and CoronaVac,have been frequently used(WHO,2023).By January 30,2023,92.9％of the entire,all-ages population had initiated vaccination and 90.6％had completed their primary series based on the whole population size reported in the seventh census of Chinese mainland(China CDC,2023).However,compared to SARS-CoV-2 mRNA vaccines,which can elicit extremely high quantities of anti-spike(S)antibodies,the levels of neutralizing antibodies induced by inactivated SARS-CoV-2 vaccines are quite lower and wane quickly(Peng et al.,2022;Lim et al.,2021).